Kenly Sikwese is the Executive Director of the AfroCAB Treatment Access Partnership. He is leading their global, regional and national level advocacy network for access to better quality optimal medicines and newer innovative diagnostics for HIV and co-infections. AfroCAB operates in 20 sub-Sahara African countries. Afrocab provides ‘patient’ education on newer and better medicines and diagnostics including demand generation.
Kenly is a currently board member of AVAC and a member of the IAS HIV Vaccine Industry Partnership. He has served as a Unitaid board member from 2016 to 2021, as Co-Chair of the UNAIDS 90-90-90 Scientific Advisory Committee (2015-2019), Co-Chair of the UNAIDS Retargeting Technical Committee (2014-2015) and as member of the Communities Delegation to the UNAIDS Programme Coordinating Board (2014-2016). Kenly has also served as a member of the INTEREST International Conference Committee from 2011 to 2016.
He has served on the World Health Organization (WHO) HIV treatment and other guideline development and technical groups since 2010 and was member of the Robert Carr Fund inaugural steering committee. Kenly has participated in WHO 2-4 CADOS and was a member of the Optimal ARVs Programme Advisory Committee of WHO, Unitaid, PEPFAR and the Global Fund. He was technical advisor for the implementation of the PLHIV Stigma Index in 12 African countries and Moldova and serves on other national, regional and global treatment access technical or advisory groups, as well as research advisory groups and was part of the WHO led group that developed the early concepts of the differentiated service delivery model.
